NZ731416A - Pyrimidinones as factor xia inhibitors - Google Patents

Pyrimidinones as factor xia inhibitors

Info

Publication number
NZ731416A
NZ731416A NZ731416A NZ73141615A NZ731416A NZ 731416 A NZ731416 A NZ 731416A NZ 731416 A NZ731416 A NZ 731416A NZ 73141615 A NZ73141615 A NZ 73141615A NZ 731416 A NZ731416 A NZ 731416A
Authority
NZ
New Zealand
Prior art keywords
independently selected
compound
pharmaceutically acceptable
tautomer
stereoisomer
Prior art date
Application number
NZ731416A
Other languages
English (en)
Other versions
NZ731416B2 (en
Inventor
Michael J Orwat
Donald J P Pinto
Ii Leon M Smith
James R Corte
Lucca Indawati De
Tianan Fang
Wu Yang
Yufeng Wang
Andrew K Dilger
Kumar Balashanmuga Pabbisetty
William R Ewing
Yeheng Zhu
Ruth R Wexler
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Priority to NZ766570A priority Critical patent/NZ766570B2/en
Publication of NZ731416A publication Critical patent/NZ731416A/en
Publication of NZ731416B2 publication Critical patent/NZ731416B2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41621,2-Diazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ731416A 2015-07-29 Pyrimidinones as factor xia inhibitors NZ731416B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ766570A NZ766570B2 (en) 2015-07-29 Pyrimidinones as factor xia inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462058316P 2014-10-01 2014-10-01
PCT/US2015/042576 WO2016053455A1 (en) 2014-10-01 2015-07-29 Pyrimidinones as factor xia inhibitors

Publications (2)

Publication Number Publication Date
NZ731416A true NZ731416A (en) 2024-01-26
NZ731416B2 NZ731416B2 (en) 2024-04-30

Family

ID=

Also Published As

Publication number Publication date
MX2020010840A (es) 2020-11-06
EA031590B1 (ru) 2019-01-31
NZ766570A (en) 2024-01-26
CA2963395A1 (en) 2016-04-07
TWI692478B (zh) 2020-05-01
PE20170939A1 (es) 2017-07-13
EP4286372A3 (en) 2024-02-21
ZA201702478B (en) 2019-06-26
TW201613923A (en) 2016-04-16
EA201790595A1 (ru) 2017-07-31
MA40123A1 (fr) 2017-09-29
SG11201702576QA (en) 2017-04-27
SI3293186T1 (sl) 2021-01-29
CN106795161B (zh) 2019-10-15
EP4286372A2 (en) 2023-12-06
BR112017006702A2 (pt) 2017-12-26
IL276470A (en) 2020-09-30
HUE038061T2 (hu) 2018-09-28
CN110734435B (zh) 2022-06-07
KR20180126612A (ko) 2018-11-27
AU2021245098A1 (en) 2021-10-28
WO2016053455A1 (en) 2016-04-07
EP3828186A3 (en) 2021-07-28
PE20210922A1 (es) 2021-05-19
JP7317905B2 (ja) 2023-07-31
JP2023134734A (ja) 2023-09-27
TWI769442B (zh) 2022-07-01
CL2017000712A1 (es) 2017-11-03
EP3293186A1 (en) 2018-03-14
IL251434B (en) 2020-08-31
HRP20171950T1 (hr) 2018-02-23
TWI834182B (zh) 2024-03-01
NO2721243T3 (US07585860-20090908-C00112.png) 2018-10-20
TN2018000229A1 (en) 2019-10-04
IL276470B (en) 2021-04-29
JP2021185182A (ja) 2021-12-09
CN114957255A (zh) 2022-08-30
CA2963395C (en) 2023-03-14
CN106795161A (zh) 2017-05-31
SI3089979T1 (sl) 2017-12-29
LT3293186T (lt) 2020-12-28
CY1123663T1 (el) 2022-03-24
JP2017530157A (ja) 2017-10-12
AU2015324530B2 (en) 2019-10-24
TW202310844A (zh) 2023-03-16
ES2836270T3 (es) 2021-06-24
RS56786B1 (sr) 2018-04-30
PH12017500580A1 (en) 2017-08-30
PL3089979T3 (pl) 2018-02-28
LT3089979T (lt) 2017-12-27
KR102269999B1 (ko) 2021-06-25
HRP20201927T1 (hr) 2021-02-05
PT3293186T (pt) 2020-12-09
AU2015324530A1 (en) 2017-05-18
PH12020500195A1 (en) 2021-02-08
CN110734435A (zh) 2020-01-31
CO2017003833A2 (es) 2017-07-11
EP3089979A1 (en) 2016-11-09
EP3293186B1 (en) 2020-09-23
AU2020200376B2 (en) 2021-07-08
SG10201911652TA (en) 2020-02-27
AR101367A1 (es) 2016-12-14
TW202043228A (zh) 2020-12-01
DK3089979T3 (en) 2018-01-15
UY36244A (es) 2016-01-29
KR101921436B1 (ko) 2018-11-22
JP6462865B2 (ja) 2019-01-30
KR20170057431A (ko) 2017-05-24
AU2021245098B2 (en) 2023-11-23
TN2017000112A1 (en) 2018-07-04
DK3293186T3 (da) 2020-12-14
MY183987A (en) 2021-03-17
ES2963267T3 (es) 2024-03-26
EP3089979B1 (en) 2017-10-18
CY1119678T1 (el) 2018-04-04
EP3828186B1 (en) 2023-08-23
EP3828186A2 (en) 2021-06-02
ES2655884T3 (es) 2018-02-22
MX2017003695A (es) 2017-05-30
PH12017500580B1 (en) 2017-08-30
JP6937734B2 (ja) 2021-09-22
JP2019069989A (ja) 2019-05-09
PT3089979T (pt) 2018-01-16
IL251434A0 (en) 2017-05-29
AU2020200376A1 (en) 2020-02-06
RS61183B1 (sr) 2021-01-29
HUE052812T2 (hu) 2021-05-28

Similar Documents

Publication Publication Date Title
HRP20171950T1 (hr) Pirimidinoni kao inhibitori faktora xia
JP2017504640A5 (US07585860-20090908-C00112.png)
JP2014521700A5 (US07585860-20090908-C00112.png)
HRP20161378T1 (hr) Dihidropiridon kao faktor xia inhibitora
PH12020552187A1 (en) Pcsk9 antagonist compounds
JP2015524443A5 (US07585860-20090908-C00112.png)
JP2017517512A5 (US07585860-20090908-C00112.png)
JP2009536218A5 (US07585860-20090908-C00112.png)
WO2015200481A8 (en) Mnk inhibitors and methods related thereto
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
RU2016150410A (ru) Ингибиторы фактора xia
IL298983A (en) Macrocyclines with P2' heterocyclic groups as factor XIA inhibitors
EA201691428A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
RU2019107938A (ru) Производное оксопиколинамида, способ его получения и его фармацевтическое применение
JP2019504905A5 (US07585860-20090908-C00112.png)
EA201391558A1 (ru) Тетрагидропиразоло[1,5-а]пиримидины как противотуберкулезные соединения
RU2012146194A (ru) Мультизамещенные ароматические соединения в качестве ингибиторов тромбина
RU2017131562A (ru) Замещенные пиразольные соединения как ингибиторы сериновых протеаз
RU2017124150A (ru) Производное дигидроиндолизинона
JP2012526769A5 (US07585860-20090908-C00112.png)
EA201592287A1 (ru) Замещенные тетрагидрокарбазольные и карбазолкарбоксамидные соединения
JP2018502137A5 (US07585860-20090908-C00112.png)
RU2017121460A (ru) Производные пиридинкарбоксамида, способ их получения и их фармацевтическое применение
AU2018250514A1 (en) Halogenopyrazoles as inhibitors of thrombin
TW201613932A (en) Organic compounds